Invictus RG’s NovoCure NVCR Stock Holding History

Invictus RG’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-38,836	Closed	-$784K	–	328
2017 Q4	$784K	Buy	+38,836	New	+$748K	0.83%	16
2016 Q1	–	Sell	-9,257	Closed	-$207K	–	667
2015 Q4	$207K	Buy	+9,257	New	+$221K	0.2%	199

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invictus RG's NVCR Position: Q1 2018 in Review

Invictus RG sold out of NovoCure (NVCR) in Q1 2018, closing a stake of 38,836 shares — an estimated $784K sold.

Invictus RG first reported a position in NVCR in Q4 2015 and held it in 2 quarters. The position peaked at $784K in Q4 2017. 129 funds tracked by Wall St. Rank hold NVCR as of Q1 2018.

Invictus RG reported no remaining NovoCure position as of Q1 2018 after selling out during the quarter.
Invictus RG sold 38,836 NovoCure shares in Q1 2018, an estimated $784K.
Invictus RG first reported a position in NovoCure in Q4 2015 and held it in 2 quarters.
Invictus RG's NovoCure position peaked at $784K in Q4 2017.
129 funds tracked by Wall St. Rank held NovoCure as of Q1 2018.

Based on Invictus RG's 13F filing for Q1 2018, filed 14 May 2018.